Logo image
Back
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study
Journal article   Peer reviewed

Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study

Aaron M. Praiss, Austin Miller, Judith Smith, Stuart M. Lichtman, Michael Bookman, Carol Aghajanian, Paul Sabbatini, Floor Backes, David E. Cohn, Peter Argenta, …
Gynecologic oncology, Vol.174, pp.213-223
07/2023
DOI: 10.1016/j.ygyno.2023.05.013
PMCID: PMC10330633
PMID: 37229879

View Online

Abstract

To determine the effects of using National Comprehensive Cancer Network (NCCN) guidelines to estimate renal function on carboplatin dosing and explore adverse effects associated with a more accurate estimation of lower creatinine clearance (CrCl). Retrospective data were obtained for 3830 of 4312 patients treated on GOG182 (NCT00011986)—a phase III trial of platinum-based chemotherapy for advanced-stage ovarian cancer. Carboplatin dose per patient on GOG182 was determined using the Jelliffe formula. We recalculated CrCl to determine dosing using Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (with/without NCCN recommended modifications) formulas. Associations between baseline CrCl and toxicity were described using the area under the receiver operating characteristic curve (AUC). Sensitivity and positive predictive values described the model's ability to discriminate between subjects with/without the adverse event. AUC statistics (range, 0.52–0.64) showed log(CrClJelliffe) was not a good predictor of grade ≥3 adverse events (anemia, thrombocytopenia, febrile neutropenia, auditory, renal, metabolic, neurologic). Of 3830 patients, 628 (16%) had CrCl <60 mL/min. Positive predictive values for adverse events ranged from 1.8%–15%. Using the Cockcroft-Gault, Cockcroft-Gault with NCCN modifications, and MDRD (instead of Jelliffe) formulas to estimate renal function resulted in a >10% decrease in carboplatin dosing in 16%, 32%, and 5.2% of patients, respectively, and a >10% increase in carboplatin dosing in 41%, 9.6% and 12% of patients, respectively. The formula used to estimate CrCl affects carboplatin dosing. Estimated CrCl <60 mL/min (by Jelliffe) did not accurately predict adverse events. Efforts continue to better predict renal function. Endorsing National Cancer Institute initiatives to broaden study eligibility, our data do not support a minimum threshold CrCl <60 mL/min as an exclusion criterion from clinical trials. •The formula used to estimate CrCl affects carboplatin dosing.•Estimated creatinine clearance (CrCl) <60 mL/min (by Jelliffe) did not accurately predict adverse events.•Our data do not support a minimum threshold CrCl <60 mL/min as exclusion criteria from clinical trials.
 Carboplatin dosing Cockcroft-Gault formula Creatinine clearance Jelliffe formula Modification of diet in renal disease formula Wright formula

Details

Metrics

23 Record Views
Logo image